Medicare Fee Schedule: Implications for Biologics Compliance
Explore how the proposed 2027 Medicare Fee Schedule affects compliance requirements for biologics, specifically addressing regulatory pathways and therapies.
CMS Narrows Medicare Drug Price Negotiation Timeline for Hyluronidase-Enhanced Biologics
CMS accelerates Medicare price negotiations for drugs with hyaluronidase, impacting biologic drug pricing and pharmaceutical companies like Halozyme Therapeutics and Johnson & Johnson.